Treatment of Helicobacter pylori infection 2012

Helicobacter

Volumn 17, Issue SUPPL.1, 2012, Pages 36-42

  Tepes, Bojan ^a   O'Connor, Anthony ^b   Gisbert, Javier P ^c   O'Morain, Colm ^b  

^a Medical Centre Roga ka   (Slovenia)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Compliance; First line therapy; Rescue therapy; Resistance; Second line therapy; Susceptibility testing

Indexed keywords

AMOXICILLIN; BISMUTH SALT; CLARITHROMYCIN; DOXYCYCLINE; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITAZOXANIDE; OMEPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RIFAXIMIN; TETRACYCLINE;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DISEASE CONTROL; DRUG CAPSULE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; INCIDENCE; LACTOBACILLUS GASSERI; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

HELICOBACTER PYLORI;

EID: 84866144665     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00981.x     Document Type: Review

References (65)

1. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-68.
2. Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J Gastroenterol 2012;47:276-83.
3. Dai WQ, Zhou YQ, Xu L, Wang BF, Fan XM, Wu JY, et al. The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study. Hepatogastroenterology 2012;59:296-9.
4. Karatapanis S, Georgopoulos SD, Papastergiou V, Skorda L, Papantoniou N, Lisgos P, et al. "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial." Acta Gastroenterol Belg 2011;74:407-12.
5. Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, et al. A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2011;23:865-70.
6. Yogeswaran K, Chen G, Cohen L, Cooper MA, Yong E, Hsieh E, et al. How well is Helicobacter pylori treated in usual practice? Can J Gastroenterol 2011;25:543-6.
7. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
8. Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori-based on polymerase chain reaction molecular test. J Gastroenterol Hepatol 2011;26:825-8.
9. Schmilovitz-Weiss H, Shalev T, Chechoulin Y, Levi Z, Yishai R, et al. High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients. Helicobacter 2011;16:229-33.
10. Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, et al. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011;66:1847-52.
11. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098-105.
12. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, et al. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012;35:56-65.
13. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012;27:504-9.
14. Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012;27:498-503.
15. Urgesi R, Pelecca G, Cianci R, Masini A, Zampaletta C, Riccioni ME, et al. Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients. Can J Gastroenterol 2011;25:315-8.
16. Tursi A, Elisei W, Giorgetti G, Picchio M, Brandimarte G. Efficacy, tolerability, and factors affecting the efficacy of the sequential therapy in curing Helicobacter pylori infection in clinical setting. J Investig Med 2011;59:917-20.
17. Kadayifci A, Uygun A, Kilciler G, Kantarcioglu M, Kara M, Ozcan A, et al. Low efficacy of clarithromycin including sequential regimens for Helicobacter pylori infection. Helicobacter 2012;17:121-6.
18. Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. Eur J Intern Med 2012;23:165-8.
19. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, et al. Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
20. Valooran GJ, Kate V, Jagdish S, Basu D. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure. Scand J Gastroenterol 2011;46:1045-50.
21. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011;16:295-300.
22. Xu MH, Zhang GY, Li CJ. Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011;40:327-31.
23. Chung JW, Lee JH, Jung HY, Yun SC, Oh TH, Choi KD, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011;16:289-94.
24. Fakheri H, Taghvaei T, Hosseini V, Bari Z. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter 2012;17:43-8.
25. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-5.
26. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34.
27. Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 2012;3:1-6.
28. Georgopoulos S, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, et al. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter 2012;17:49-53.
29. Toros AB, Ince AT, Kesici B, Saglam M, Polat Z, Uygun A. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobacter 2011;16:225-8.
30. Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, et al. Efficacy of levofloxacin and rifaximin-based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785-90.
31. Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011;49:987-93.
32. Shokrzadeh L, Jafari F, Dabiri H, Baghaei K, Zojaji H, Alizadeh AH, et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol 2011;17:261-4.
33. Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli J Jr. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol 2011;48:261-4.
34. De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, et al. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointestin Liver Dis 2011;20:235-9.
35. Nishizawa T, Suzuki H, Matsuzaki J, Muraoka H, Tsugawa H, Hirata K, et al. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother 2011;55:5374-5.
36. Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 2011;26:1457-61.
37. Kim JY, Kim N, Park HK, Jo HJ, Shin CM, Lee SH, et al. Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea. Korean J Gastroenterol 2011;58:74-81.
38. Miendje Deyi VY, Bontems P, Vanderpas J, De Koster E, Ntounda R, Van den Borre C, et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol 2011;49:2200-9.
39. Ayala G, Galván-Portillo M, Chihu L, Fierros G, Sánchez A, et al., Study Group Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico. Microb Drug Resist 2011;17:149-55.
40. Goh KL, Manikam J, Qua CS. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2012;35:1097-102.
41. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011;16:420-6.
42. Sezikli M, Cetinkaya ZA, Güzelbulut F, Yeşil A, Alt Nöz ME, Ulu N, et al. Efficacy of the combination of tetracycline, amoxicillin, and lansoprazole in the eradication of Helicobacter pylori in treatment-naïve patients and in patients who are not responsive to clarithromycin-based regimens: A Pilot Study. Gut Liver 2012;6:41-4.
43. Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011;16:234-40.
44. Hu TH, Chuah SK, Hsu PI, Wu DC, Tai WC, Chiu YC, et al. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011;342:177-81.
45. Ermis F, Akyuz F, Uyanikoglu A, Kurt R, Pinarbasi B, Nazik H, et al. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. South Med J 2011;104:579-83.
46. Hirata Y, Ohmae T, Yanai A, Sakitani K, Hayakawa Y, Yoshida S, et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents 2012;39:352-5.
47. Gu LY, Lin WW, Lu H, Chen XY, Ge ZZ, Li XB. Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study. Helicobacter 2011;16:284-8.
48. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol 2012;18:11-7.
49. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012;35:209-21.
50. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, Cosme A, Molina-Infante J, Rodrigo L, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012;35:941-7.
51. Lee SK, Lee SW, Park JY, Kwon BS, Kim SY, Hyun JJ, et al. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter 2011;16:410-4.
52. Deguchi R, Nakaminami H, Rinbara E, Noguchi N, Sasatsu M, Suzuki T, et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol 2011;27:888-92.
53. Tokoro C, Inamori M, Koide T, Sekino Y, Iida H, Sakamoto Y, et al. Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication. Med Sci Monit 2011;17:CR235-40.
54. Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, et al. Anti-Helicobacter pylori activity of Terminalia macroptera root. Fitoterapia 2012;83:872-6 PubMed PMID: 22465506.
55. Lawal TO, Adeniyi BA, Moody JO, Mahady GB. Combination Studies of Eucalyptus torelliana F. Muell. leaf extracts and clarithromycin on Helicobacter pylori. Phytother Res 2012;50:92-8 PubMed PMID: 22318891.
56. Njume C, Afolayan AJ, Samie A, Ndip RN. Inhibitory and bactericidal potential of crude acetone extracts of Combretum molle (Combretaceae) on drug-resistant strains of Helicobacter pylori. J Health Popul Nutr 2011;29:438-45.
57. Njume C, Afolayan AJ, Green E, Ndip RN. Volatile compounds in the stem bark of Sclerocarya birrea (Anacardiaceae) possess antimicrobial activity against drug-resistant strains of Helicobacter pylori. Int J Antimicrob Agents 2011;38:319-24.
58. Suk KT, Baik SK, Kim HS, Park SM, Paeng KJ, Uh Y, et al. Antibacterial effects of the urushiol component in the sap of the lacquer tree (Rhus verniciflua Stokes) on Helicobacter pylori. Helicobacter 2011;16:434-43.
59. Sezikli M, Cetinkaya ZA, Güzelbulut F, Sezikli H, Özkara S, Coşgun S, et al. Efficacy of vitamins supplementation to therapy on Helicobacter pylori eradication in patients with low antioxidant capacity. Clin Res Hepatol Gastroenterol 2011;35:745-9.
60. Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr 2011;106:1632-7. Epub 2011 Aug 3. PubMed PMID: 21810287.
61. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011;8:79-88.
62. Soto G, Bautista CT, Roth DE, Gilman RH, Velapatiño B, Ogura M, et al., Gastrointestinal Physiology Working Group in Peru Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J Infect Dis 2003;188:1263-75.
63. Dhar A. Acquisition of Helicobacter pylori and reinfection after eradication. Indian J Gastroenterol 2001;20:78-9.
64. Saha SK, Saha SK, Masud H, Islam N, Raihan A, Roy P, et al. To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients Bangladesh. Med Res Counc Bull 2011;37:83-7.
65. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. The European Helicobacter Study Group (EHSG). Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.